Use of Proton-Pump Inhibitor Is Not Associated with Adverse Clinical Outcomes in COVID-19 Patients: A Territory-Wide Cohort Study

Figure 1

Cumulative incidence of primary endpoint (a composite endpoint of intensive care unit admission, use of invasive mechanical ventilation, and death) in patients with SARS-CoV-2 infection/COVID-19 who were and were not PPI users after (a) propensity score weighting and (b) propensity score matching in a single multiple imputation data set. COVID-19: coronavirus disease 2019; PPI: proton-pump inhibitor; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

(a)

(b)